1. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
    Briana M. Choi et al, 2021, Journal of Medical Economics CrossRef
  2. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials
    Aditi A Kharat et al, 2021, Journal of Managed Care & Specialty Pharmacy CrossRef
  3. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma
    Yoshihiko Fukukura et al, 2019, Pancreas CrossRef
  4. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma
    Satoshi Okubo et al, 2019, Scientific Reports CrossRef
  5. Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma
    Nan Lee et al, 2021, Cancer Biomarkers CrossRef
  6. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
    Taiga Otsuka et al, 2021, International Journal of Clinical Oncology CrossRef
  7. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma
    Yoshihiko Fukukura et al, 2020, Pancreatology CrossRef
  8. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
    Kosuke Morimoto et al, 2022, Value in Health Regional Issues CrossRef